Purpose: Abdominal aortic aneurysms (AAA) have a multifactorial pathology with both genetic and environmental risk factors. Recent genome-wide association studies (GWAS) have discovered ten genetic risk loci for AAA. To what extent these genetic loci contribute to the aneurysm pathology is yet unknown. This study aims to investigate whether genetic risk variants are associated with three clinical features: diameter of aneurysm sac, type of artery and symptoms.
Introduction
Abdominal aortic aneurysm disease (AAA) is a vascular pathology, affecting in particular elderly Western men. [1] [2] [3] Besides gender and smoking, a positive family history is a known predisposing factor for occurrence of the disease, [4] [5] indicative of a strong heritable component to AAA.
In the past decade, genome-wide association studies (GWAS) have uncovered nine common genetic variants, i.e. single-nucleotide polymorphisms (SNPs), associated to AAA susceptibility. [6] [7] [8] [9] [10] [11] [12] While these GWAS point to part of the genetic underpinnings of AAA, the extent to which these variants influence the clinical presentation or how these loci contribute to pathology of the disease is still largely unknown.
Previous literature has shown many complex traits to be polygenic in origin, comprising small effects of hundreds or even thousands of common variants that in aggregate explain a substantial proportion of trait susceptibility and heritability. [13] [14] [15] For example, the International Schizophrenia Consortium [16] summarized weighted genetic effects [13] across nominally associated loci at increasingly liberal p-value thresholds into polygenic risk scores (PRS), and correlated PRS to disease susceptibility, demonstrating that a PRS can provide a reliable genetic indicator for clinical outcome.
In the present study, we investigated whether AAA susceptibility variants in aggregate are associated with three clinical phenotypes (maximum diameter of aneurysm sac, aneurysm-related symptoms, and type of artery) within the Aneurysm-Express Biobank Study [17] These phenotypes encompass intervention matters and are therefore clinically relevant. First, we constructed a weighted PRS based on summary level GWAS data for AAA [12] using increasingly liberal p-value thresholds and modeled a best fit PRS.
Secondly, we tested the genome-wide significant risk SNPs for association with the selected clinical phenotypes in our cohort of patients with clinically manifested disease. Our results show that higher PRS associates to larger aneurysm diameter, but no association was found with clinical symptoms or type of artery.
Methods

Aneurysm-Express Biobank Study
The Aneurysm-Express is a biobank study that contains aneurysm sac tissue from patients undergoing open surgical repair of arterial aneurysms. The study design has been published previously. [17] Briefly, the study was approved by local medical ethics committee, eligible patients were operated in two different Dutch hospitals and all participants gave informed consent. All research was conducted according to the principles of the Declaration of Helsinki and its later amendments. For the present study we 
Genotyping, quality control, and imputation
DNA of 503 patients in Aneurysm-Express Biobank Study was extracted from whole blood EDTA or (when no blood was available) aneurysm tissue samples following standardized in-house validated protocols for the Aneurysm-Express Genomics Study (AAAGS). Samples were sent for genotyping at the Genomic Analysis Center of the Helmholtz Zentrum Münich (Germany) according to OECD standards under study number M00750 using the Illumina HumanCoreExome BeadArray v1.1 (Illumina Inc., www.illumina.com).
Genotype calling was done with the GenomeStudio V2011.1 software and the Genotyping module version 1.9.4 using the original Illumina cluster and manifest files (humancoreexome-12v1-1_a.egt and HumanCoreExome-12-v1-1-C.bpm). The GenCall score cutoff was 0.15 as recommended by Illumina.
The average call rate of all samples was 99.55% across 542,585 variants.
Subsequently, community standard quality control (QC) procedures were applied [18] to obtain high quality data. Samples with low average genotype calling and sex discrepancies (compared to the clinical data available) based on GenomeStudio metrics were excluded. The data was filtered on 1) individual (sample) call rate >97%, 2) SNP call rate >96%, 3) average heterozygosity rate ± 2.5 s.d., 4) relatedness (pi-hat > 0.20), 5) Hardy-Weinberg Equilibrium (HWE p < 1.0x10 -6 ), and 6) population stratification excluding non-Europeans (based on 1000G phase 3). [19] zCall [20] was used to call missing exomevariants after QC. After QC and resulted in 478 samples and 541,569 variants (call rate = 99.99%) remained and were used for imputation.
Autosomal missing genotypes were imputed based on phased integrated data from 1000 Genomes (phase 3, version 5) and Genome of the Netherlands v5 [21] using IMPUTE2 (v2.3.0) [22] after pre-phasing genotyped data with SHAPEIT2 (v2.644). [23] Polygenic Risk Score (PRS)
We used the PRSice software [13] for creating the best fit PRS per phenotype by comparing scores across a range of different p-value thresholds. In short, PRSice calculates weighted PRS based on the estimated effects reported [12, 39] : variants are pruned based on the linkage disequilibrium (r 2 < 0.1, clump, range 500 kb) [20] as observed in AAAGS for bins of increasingly liberal p-value thresholds (p T , see
Supplemental Table 1 ) preferentially keeping variants with lower p-values as reported by the metaanalysis of GWAS [12] (similar to the --clump algorithm in PLINK [24] ). Odds ratios were natural log transformed to betas (β), we only included variants with MAF > 0.05 and imputation quality info-score > 0.8. In order to verify the predictive value of the PRS of the AAA-GWAS, we additionally modeled a PRS of summary statistics of the attention deficit hyperactivity disorder (ADHD) GWAS unrelated to AAA, [39] and tested this additional polygenic score for association with the selected clinical parameters in our study cohort.
Individual SNP analysis
We selected nine SNPs that were identified in a recent GWAS meta-analysis for AAA. [12] These SNPs were tested for association with the clinical features separately. For the SNP lookup we used GWASToolKit (https://github.com/swvanderlaan/GWASToolKit, doi: 10.5281/zenodo.997862), which is a collection of scripts to execute SNPTEST v2.5.3 [25] analyses. Given the limited sample size, we calculated the expected power for this analysis. [26] In case of a risk allele frequency of <20%, and estimated OR of 1.10, the resulting power is ±80% (Supplemental Figure 1) .
Primary endpoints
The primary outcomes or phenotypes were artery type, symptoms, and diameter of the aneurysm sac.
Artery type was defined as either aortic, or peripheral (iliac, femoral, popliteal, and carotid). Symptom status was defined as asymptomatic, or any aneurysm-related symptoms like thromboembolic events, local pain or swelling, or rupture of the aneurysm sac. Maximum diameter was measured by experienced radiologists at time of inclusion, on the double oblique plane of computed tomography angiography.
Statistical analysis
PRS and individual SNP analyses were performed using linear and logistic regression models where appropriate, adjusted for sex, age, ancestral background using four principal components, smoking status, and diameter of the aneurysm sac or artery type if applicable. Nagelkerke's r2 was used as a metric of the 
Results
In the present study, the Aneurysm-Express biobank comprised a total of 415 patients, average age of 69±8.1 years-old, whose majority (85%) is male, and 349 (84%) patients were treated for an AAA (Table   1) .
We used summary statistics from the largest meta-GWAS for AAA [12] so far to calculate weighted polygenic scores at increasingly liberal p-value thresholds (p T , Supplemental Table 1 ) and correlated these to artery type, symptoms, and diameter of the aneurysm sac ( Figure 1A-C) . A PRS including 272 variants at p T of 0.01015 explained the largest proportion in diameter (R 2 = 0.019, p =0.001, Supplemental Table   2 ). Distributions of the AAA-PRS for diameter was comparable between artery types (Kruskal-Wallis test p-value = 0.135, Supplemental Figure 2 ). No association was found for artery type and symptom status (Supplemental Table 2 ). We verified all AAA-PRS findings with another unrelated PRS derived from a ADHD GWAS, [39] and correlated these with the selected clinical parameters in our study cohort ( Figure   1D -F). No associations with the ADHD-PRS were observed ( Figure 1D -F, Supplementary Table 3 ).
Next, we tested ten known AAA SNPs for association with diameter of the aneurysm sac (Table 2) , artery type and symptom status (Supplemental Table 3 ). For diameter, a nominal association was found with rs1466535 (12q13.3, LRP1, p = 0.013). For rs602633 (1p13.3, PSRC1-CELSR2-SORT1), rs1795061 (1q32.3, SMYD2), rs2836411 (21q22.2, ERG) and rs1466535 a concordant effect direction was observed.
For six risk variants, the effect direction was disconcordant with the GWAS results.
Discussion
In this study, we investigated the association of genetic susceptibility variants with clinical phenotypes within a biobank consisting of both aortic and peripheral aneurysms. We demonstrated that within our Aneurysm-Express biobank cohort, polygenic scores of AAA susceptibility was associated with diameter of the aneurysm sac. No association was found with clinical symptoms or type of artery.
The clinical translation of genetic research has been a topic of interest for the last decades. For rare diseases like Marfan or Ehlers-Danlos syndrome, genetic clinical utility has been proven and applied, [27] but for more common complex diseases like AAA, the interpretation and translation of large-scale genetic studies is challenging at best. [28] GWAS-derived association studies were mainly investigated in intracranial and abdominal aneurysm patients. [29] [30] [31] [32] [33] [34] The majority of these studies used a genetic risk score (GRS) based on the index SNPs from GWAS to study additional genetic predicting value to models consisting of demographic characteristics and health parameters. A previous study using a GRS including 4 variants showed that a high GRS was associated with aneurysm growth rate independent of baseline abdominal aortic size. [38] Recently, a similarly calculated, but polygenic risk approach has proved clinical utility in atherosclerosis, statin therapy, and breast cancer. [35] [36] [37] A polygenic approach can optimize power by using a liberal p-value threshold, enforced by the evidence that additive weakly effects of nominally associated common variants explain part of the heritability of, and susceptibility to common complex diseases. [14, 15] Our study uses a polygenic risk approach within a cohort comprising both aortic and peripheral aneurysm patients and shows that a high polygenic risk of AAA is associated to larger diameter of the aneurysm sac.
After correcting for multiple testing, no relevant effects of individual SNPs were observed, and the majority of the effect directions in our analysis are discordant with the recent GWAS meta-analysis. [12] This is probably mainly due to limited size and power of both the published GWAS (4,972 cases and 99,858 controls) and our present study (Supp. Figure 2 ). Differences could also be explained by differences in inclusion criteria; the GWAS analysis is performed in patients with AAA ≥ 30mm, including smaller AAA that have been followed-up and was compared to healthy subjects. [28] In contrast, our cohort consists of only patients including symptomatic patients or progressive aneurysmal disease that requires surgical treatment. For this, it is arguable that other risk variants have a more prominent role in further deterioration of the vessel wall and have another direction than GWAS identified loci that may contribute particularly to initiation of aneurysmal disease.
Whether aortic and intracranial aneurysms share genetic susceptibility, was earlier investigated in a GWAS of four cohorts. [31] These studies provide evidence that variants at 9p21, 18q11, 15q21, and 
Conclusions
In conclusion, we show that a weighted polygenic score of AAA susceptibility explained 1. Supplementary Table 2&3 . D-E-F indicate unrelated PRS derived from ADHD GWAS summary statistics [39] , showing no association with any of the selected clinical phenotypes in the Aneurysm-Express Biobank cohort. Abbreviations: PRS = polygenic risk score, ADHD = attention deficit hyperactivity disorder, GWAS = genome-wide association study. Tables   Table 1   Table 1 
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